Initial combinations of empagliflozin and metformin in patients with type 2 diabetes

被引：0
|
作者：
Hadjadj, S. [1 ,2 ]
Jelaska, A. [3 ]
Zhang, S. [3 ]
Meinicke, T. [4 ]
Woerle, H. J. [5 ]
Broedl, U. C. [5 ]
机构：
[1] Ctr Hosp Univ Poitiers, Poitiers, France
[2] INSERM, CIC 1402, Poitiers, France
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
733
引用
收藏
页码：S350 / S350
页数：1
相关论文
共 50 条
  • [1] Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
    Hadjadj, Samy
    Rosenstock, Julio
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2016, 39 (10) : 1718 - 1728
  • [2] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [3] Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1484): : 172 - 174
  • [4] Combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with Type 2 diabetes
    Defronzo, R. A.
    Lewin, A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [5] Empagliflozin as add-on to metformin plus sulfonylurea in patients with Type 2 diabetes
    Haering, H. U.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [6] Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Haering, Hans-Ulrich
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) : 82 - 90
  • [7] Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes
    Kovacs, C. S.
    Seshiah, V.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Stella, P.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 88 - 88
  • [8] Initial combination of metformin, sitagliptin, and empagliflozin in drug-naive patients with type 2 diabetes: Safety and metabolic effects
    Lim, Soo
    Sohn, Minji
    Shin, Yujin
    Ferrannini, Ele
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 757 - 762
  • [9] Empagliflozin as add-on to metformin in people with Type 2 diabetes
    Merker, L.
    Haering, H-U.
    Christiansen, A. V.
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 (12) : 1555 - 1567
  • [10] The safety of empagliflozin plus metformin for the treatment of type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 837 - 848
12345